ArticleOncotarget2016

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).

Loic Lebellec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.